Salvatore Siena, MD, provides an overview of the DESTINY-CRC01 trial in DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer.
Salvatore Siena, MD, professor of medical oncology at Universita degli Studi di Milano and director of Niguarda Cancer Center at Grande Ospedale Metropolitano Niguarda in Italy, provides an overview of the DESTINY-CRC01 trial in HER2-positive metastatic colorectal cancer (CRC).
The phase 2 trial evaluated fam-trastuzumab deruxtecan-nxki (Enhertu), says Siena. Trastuzumab deruxtecan isan antibody-drug conjugate with a cleavable tetrapeptide-based linker and a topoisomerase 1 inhibitor that has demonstrated activity in HER2-expressing cancers, Siena adds.
DESTINY-CRC01 enrolled patients into 3 cohorts, explains Siena. Cohort A enrolled 53 patients with either primary tumors or metastasized tumors expressing HER2 to a level of immunohistochemistry (IHC) 3+ or 2+ and in-situ hybridization (ISH)–positive, Siena explains. Cohort B evaluated 7 patients with IHC 2+ but in-situ hybridization–negative tumors. Finally, cohort C, made up of 18 patients, included those with IHC 1+ disease, Siena concludes.